迪威爾(688377.SH):股東楊建民及其一致行動人持股比例由14.35%減至9.35%
格隆匯3月4日丨迪威爾(688377.SH)公佈,2022年3月4日,公司收到股東楊建民發來的《簡式權益變動報吿書》,2021年8月10日至2022年3月4日,楊建民累計減持973.335萬股,減持比例5.00%。
本次權益變動後,信息披露義務人楊建民及其一致行動人楊舒合計持有公司18,216,650股,均為無限售條件流通股,占上市公司股本總額的9.35%,持股比例由14.35%變為9.35%,持有股份權益變動已達5%。其中,楊建民持有公司12,016,650股,占上市公司股本總額的6.17%,楊舒持有公司股份6,200,000股,佔公司總股本的3.18%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.